Biography
Dr. Melvin George leads the Centre for Clinical Trials and Research at SRM Medical College Hospital, overseeing first-in-human through phase IV programmes across therapeutic areas. His work bridges translational pharmacology and regulatory-grade trial execution.
Govt funded projects as PI:
- Phase 3 Dengue vaccine trial
- Acute coronary syndrome prognostic biomarkers
- Indian Cardiovascular Research Advocacy Group 2 -ICMR CAR project- regional centre (PI)
- Epigenetic aging & CAD
Other major projects as the investigator
- TIPS-3 polypill study – phase 3 clinical trial for polypill in patients with high cardiovascular risk (2014-2020)
- ODYSSEY Outcomes study –phase 3 clinical trial on Alirocumab in post-acute coronary syndrome (2014-2018)
- ACT study – clinical trial for Colchicine in COVID infection (2020-2022)
- Phase 1 & phase 2 clinical trial for Covaxin- inactivated whole cell Virion vaccine in healthy volunteers – BBIL (2020-2021)
- Phase 3 clinical trial for Covaxin- inactivated whole cell Virion vaccine in healthy volunteers BBIL- (2020-2022)
- Indian COPD Registry (2022-2024)
- Heart Failure Registry (2022-2024)
- UNISUS study – Phase 3 clinical trial on macitentan in pulmonary arterial hypertension (2023- 2025)
Significant achievements
Recognized as Nodal Officer, ICMR Centre for Clinical Trials at SRM Medical College through ICMR
Key Responsibilities
- General Secretary, Association of Clinical Pharmacologists of India
- Treasurer, Medical Pharmacologists Society
- Chairperson, Gleneagles Hospital IEC, Chennai
- Chairperson, Chettinad Medical College, Chennai
- Member Secretary, SRM MCH Ethics Committee, Chennai
- Member, Pushpagiri Medical College IRB, Kerala
- Member, Tambaram IMA Ethics Committee, Chennai
- Member, Indian Society of Clinical Research
- Member, National Association of Pharmacology & Therapeutics
- Member, Forum for Ethics Review Committees in India
Research Interests
Ongoing trials
- A Phase II/III, Multicentre, Observer-Blind, Randomized, Activecontrolled Study to Evaluate Immunogenicity and Safety of a Trivalent Nanoparticle Influenza Vaccine and Covid-Influenza Combination Vaccine Compared with Licensed Influenza and Covid -19 Vaccines in Adults
- A phase 2/3, double-blind, randomized, active-controlled, multicentric study to evaluate the safety, immunogenicity and lot-to-lot consistency of a bivalent conjugate vaccine against Salmonella enterica serovars Typhi and Paratyphi A in healthy individuals aged 6 months to 65 years.
- A study in India to explain the safety and immunogenicity of Respiratory syncytial virus (RSV) vaccine in adults
- A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Immunogenicity and Safety of Single dose of Dengue Tetravalent Vaccine, Live Attenuated (Recombinant, Lyophilized) – "DengiAll" of Panacea Biotec Limited in Healthy Indian Adults
- Selatogrel Outcome Study in suspected Acute Myocardial Infarction (SOS-AMI) Multi-center, double-blind, randomized, placebo-controlled, parallel-group study to evaluate the efficacy and safety of self-administered subcutaneous selatogrel for prevention of all-cause death and treatment of acute myocardial infarction in subjects with a recent history of acute myocardial infarction
- A Phase 3, Prospective, multicentre, double blinded, double-dummy, randomized, active controlled, parallel-group, group sequential, adaptive, event-driven study to compare efficacy, safety and tolerability of Macitentan 10mg in patients with pulmonary arterial hypertension, followed by an open- label treatment period with Macitentan 75mg
- Effect, cost, and sustainability of a synergistic, multipronged, customized, low-cost intervention package to reduce cArdiovascular Burden across India: a cLuster RCT
- Evaluation of Epigenetic Aging and its Modulation by Beta-Nicotinamide Mononucleotide (Beta-NMN) in Patients Diagnosed with Coronary Artery Disease
- A First-in-human, Randomized, Double-Blind, Placebo-Controlled, Phase I Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of a Recombinant Live-Attenuated Zika Vaccine (Freeze Dried) of Human Biologicals Institute, in Healthy Adult Volunteers aged 18 to 50 years.
- A seamless, randomized, double-blind, placebo-controlled single-centre Phase I study in healthy Indian adult participants followed by an active comparator controlled, multi-centric Phase II open label study in healthy adult participants and an elderly population to evaluate the safety, reactogenicity, and immunogenicity of Mynflu001, a recombinant, adjuvanted Influenza Vaccine.
- Cardiovascular pharmacology
- Vaccine trials
- Pharmacovigilance
- Translational biomarkers
Awards
Grants received
ICMR Funded Projects
- Evaluation of Epigenetic Aging and its Modulation by Beta-Nicotinamide Mononucleotide (Beta-NMN) in Patients Diagnosed with Coronary Artery Disease INR 94,67,093
- A Phase III, Multicentre, Randomized, Double-Blind, Placebo- Controlled Study to Evaluate the Efficacy, Immunogenicity and Safety of Single dose of Dengue Tetravalent Vaccine, Live Attenuated (Recombinant, Lyophilized) – “DengiAll” of Panacea Biotec Limited in Healthy Indian Adults (Protocol version: 5.0 dated 27 Oct 2025) INR 92,63,531
- Effect, cost, and sustaiNability of a synergistic, multipronged, customized, low-cost intervention package to reduce cArdiovascular Burden across India: a cLustEr RCT INR 1,03,82,589
- A seamless, randomized, double-blind, placebo-controlled single centre Phase I study in healthy Indian adults, followed by an active comparator controlled, multi-centric Phase II open-label study in healthy adult participants and an elderly population to evaluate the safety, reactogenicity, and immunogenicity of Test Vaccine, a recombinant, adjuvanted Influenza Vaccine INR 4,78,75,713
Publications
- Masilamani M, George M. Regulatory Landscape of Clinical Trials in India: Current Trends and Future Prospects. Ther Innov Regul Sci. 2026;60(1):45-58.
- Bibi R, George M, Sarkar K. STAT4 mediated modulation of T-B cell interactions profiling in NSCLC. Mol Biol Rep. 2026;53(1):112.
- Mukherjee O, George M, Sarkar K. STAT2 Mediated Epigenetic and Epitranscriptomic Regulation of T Helper Cell Differentiation. Immunology. 2026;170(2):210-225.
- Mani V, George M, et al. Assessment of intrinsic capacity using step 2 assessment tools among older adults in India. Aging Clin Exp Res. 2026;38(1):88-96.
- Mukherjee O, Bose S, George M, Sarkar K. Involvement of CCCTC-binding factor (CTCF) in immunomodulation and epigenetic regulation of T helper cell differentiation. Clin Immunol. 2026;250:109-120.
- Bibi R, George M, Sarkar K. RNA-guided STAT3 modification fine tunes the epigenetic and epitranscriptomic landscape in NSCLC. Med Oncol. 2025;42(3):45.
- Roy S, Shanmugam G, George M, Sarkar K. Brahmi (Bacopa monnieri) plant preparation facilitates immunotherapeutic modulation in invasive ductal carcinoma. J Cancer Res Clin Oncol. 2025;151(2):332-345.
- Bibi R, George M, Sarkar K. Role of Trichostatin A (TSA) in modulating the epigenetic landscape of CD4+ T cells. Clin Epigenetics. 2025;17(1):12.
- Bindu S, Mukherjee O, George M, Sarkar K. Interferon-alpha 2b (IFNα2b) enhances monocyte-derived dendritic cell maturation and immune function. Mol Biol Rep. 2025;52(4):201-210.
- Bibi R, George M, Sarkar K. Epigenetic and Epitranscriptomic Modulation by STAT1: Unraveling T Helper Cell Differentiation in NSCLC. J Immunother. 2025;48(2):88-97.
- Bibi R, George M, Sarkar K. Epigenetic control of T helper cells differentiation via STAT3 signaling in lung cancer. Med Oncol. 2025;42(1):15.
- Goenka L, George M, et al. Evaluation of the current status of ethics committees in India: A cross-sectional survey. Perspect Clin Res. 2025;16(1):22-30.
- Masilamani M, George M. The Epigenetic Landscape: From Molecular Mechanisms to Biological Aging. Rejuvenation Res. 2025;28(1):5-18.
- Bibi R, George M, Sarkar K. Exploring the regulatory role of mtTFA in T helper cell-mediated immune responses. Int Immunopharmacol. 2025;140:112-125.
Jinson J, George M, et al. Development of a near infrared region based non-invasive therapy device for wound healing. Sci Rep. 2024;14:15234. - Masilamani M, George M. Clinical trial trends over the last 5 years among the BRICS nations. Perspect Clin Res. 2024;15(3):134-140.
- Mukherjee O, George M, Sarkar K. WASp-deficient Th1 cells exhibit altered epigenetic landscapes in inflammatory conditions. Clin Immunol. 2024;242:109-118.
- Roy S, George M, Sarkar K. Immunomodulatory effects of Diospyros peregrina fruit preparation in experimental oncology. Med Oncol. 2024;41(5):102.
- Bibi R, George M, Sarkar K. Association of WASp in epigenetic regulation of T helper cells. Med Oncol. 2023;40(12):356.
Bibi R, George M, Sarkar K. Doxorubicin induced epigenetic regulation of dendritic cell maturation. Pathol Res Pract. 2024;254:155-164. - Venugopal P, George M, et al. Prediction of maternal and foetal outcomes among patients with preeclampsia using biomarkers. Placenta. 2023;138:45-52.
- Bibi R, George M, Sarkar K. HDAC inhibition regulates oxidative stress in CD4+ T helper cells. Int Immunopharmacol. 2023;120:110-120.
- Goenka L, George M. Fathoming the Role of Semaglutide in Obesity Therapeutics. Clin Ther. 2023;45(8):712-724.
- Bibi R, George M, Sarkar K. Depletion of EZH2 directs transcription factors in T helper cell differentiation. Med Oncol. 2023;40(6):182.
- Bhootra S, George M, Sarkar K. Diospyros malabarica fruit preparation mediates immunotherapeutic modulation in NSCLC. J Ethnopharmacol. 2023;312:116-128.
- Goenka L, George M. Evaluation of Endpoints Used in Clinical Trials on Adenomyosis. Rev Recent Clin Trials. 2023;18(2):98-105.
- Surendran AM, George M, Sarkar K. Immunomodulatory Role of Diospyros peregrina in Breast Cancer. Clin Breast Cancer. 2023;23(4):345-356.
- Shanmugam G, George M, Sarkar K. Electropotential-Inspired Star-Shaped Gold Nanoconfined MWCNTs for Biosensing. ACS Appl Bio Mater. 2022;5(9):4120-4132.
- Venugopal P, George M, et al. Prioritization of microRNA biomarkers for a prospective evaluation in myocardial infarction. Front Cardiovasc Med. 2022;9:856412.
- Idhrees M, George M, et al. The motivators and barriers to a career in cardiothoracic surgery in India. Indian J Thorac Cardiovasc Surg. 2022;38:156-164.
- Bibi R, George M, Sarkar K. Involvement of inflammatory cytokines and mtTFA complex in T helper cell senescence. Mol Immunol. 2022;148:12-24.
- Mukherjee O, George M, Sarkar K. Involvement of XPG in immunomodulatory signaling in CD4+ cells. Immunobiology. 2022;227(4):152-162.
- Bibi R, George M, Sarkar K. T helper cell-mediated epitranscriptomic regulation via m6A RNA methylation. J Cancer Res Clin Oncol. 2022;148(5):1012-1025.
- Goenka L, George M, et al. Knowledge and attitudes on plagiarism among undergraduate medical students in India. BMC Med Educ. 2022;22:156.
- Goenka L, George M. Efficacy of pharmacological interventions in COVID-19: A systematic review. Br J Clin Pharmacol. 2022;88(6):2534-2550.
- Goenka L, George M. Evaluation of pharmacological interventions in the management of adenomyosis. Eur J Clin Pharmacol. 2022;78(4):512-524.
- Bibi R, George M, Sarkar K. R-loop modulated epigenetic regulation in T helper cells during cancer. Transl Oncol. 2021;14(8):101124.
- Howard C, George M, et al. TEVAR for complicated and uncomplicated type B aortic dissection: Systematic review. J Card Surg. 2021;36(10):3820-3830.
- Roy S, George M, Sarkar K. Diospyros Peregrina Mediated Immunomodulation of Lymphocytes. Iran J Immunol. 2021;18(2):145-156.
- Shanmugam S, George M, et al. Clinical outcomes among COVID-19 patients managed with modern and Siddha medicine. J Ayurveda Integr Med. 2022;13(1):100412.
- Goenka L, George M, et al. Attitudes on plagiarism among post-graduate resident doctors in India. BMJ Open. 2021;11(6):e045612.
- Venugopal P, George M, et al. Alirocumab in Post ACS Patients - Saving Lives at a Premium. Curr Cardiol Rev. 2022;18(1):e120521193356.
- Srivatsan V, George M, et al. Assessment of PBMC Senescence and Endothelial Dysfunction in CAD. Arq Bras Cardiol. 2021;116(5):940-948.
- George M, et al. Clinical Pharmacokinetic Drug Interaction Potential of MenoAct851. Curr Ther Res Clin Exp. 2020;92:100588.
- Srivatsan V, George M, et al. Long Term Prognostic Utility of MMP-9 in Acute Coronary Syndrome. Curr Pharm Biotechnol. 2021;22(4):512-524.
- George M, et al. Factors Influencing Levels of ST-2, Galectin-3 and MMP-9 in ACS. Cardiovasc Hematol Disord. 2020;20(2):124-132.
- Goenka L, George M, et al. Assessment of quality of RCTs published in Indian medical journals. Perspect Clin Res. 2019;10(2):79-83.
- Goenka L, George M. Neuroprotective agents in Acute Ischemic Stroke-A Reality Check. Biomed Pharmacother. 2019;109:2539-2547.
- Goenka L, George M. The Ascent of Mineralocorticoid Receptor Antagonists in Diabetic Nephropathy. Curr Clin Pharmacol. 2019;14(2):78-83.
- Goenka L, George M. Novel approaches in the treatment of diabetic cardiomyopathy. Biomed Pharmacother. 2018;104:412-422.
- Jha D, George M, et al. Prognostic role of soluble ST2 in acute coronary syndrome with diabetes. Eur J Clin Invest. 2018;48(9):e12994.
- George M, et al. Do ANGPTL-4 and galectin-3 reflect the severity of coronary artery disease? Ther Adv Cardiovasc Dis. 2017;11(1):15-24.
- Goenka L, George M. A peek into the drug development scenario of endometriosis. Biomed Pharmacother. 2017;90:575-585.
- George M, et al. Effect of metformin on exercise capacity in metabolic syndrome. Diabetes Metab Syndr. 2017;11:S31-S37.
- George M, et al. End points in heart failure-are we doing it right? Eur J Clin Pharmacol. 2017;73(4):395-404.
- Shanmugam E, George M, et al. Effect of tolvaptan on acute heart failure with hyponatremia. Indian Heart J. 2016;68:S15-S21.
- George M, et al. Molecular analysis of the LDLR gene in coronary artery disease patients in India. Clin Biochem. 2016;49(7-8):552-560.
- George M, et al. Evaluation of Endothelial and Platelet Derived Microparticles in ACS. J Clin Diagn Res. 2015;9(12):OC09-12.
- George M, et al. GDF 15—A Novel Biomarker in the Offing for Heart Failure. Curr Cardiol Rev. 2016;12(1):37-46.
- Palaniappan M, George M, et al. Pattern of Adverse Drug Reactions Reported with Cardiovascular Drugs. J Clin Diagn Res. 2015;9(11):FC01-04.
- George M, et al. Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition. J Cardiovasc Pharmacol. 2016;67(1):15-22.
- George M, et al. Value of pentraxin-3 and galectin-3 in acute coronary syndrome. Ther Adv Cardiovasc Dis. 2015;9(5):275-284.
- Sandhiya S, George M, et al. Comparison of ranolazine and trimetazidine in diabetic CAD patients. J Clin Diagn Res. 2015;9(1):OC01-05.
- George M, et al. Riociguat: Something new in pulmonary hypertension therapeutics? J Pharmacol Pharmacother. 2015;6(1):3-8.
- Srivatsan V, George M, et al. Utility of galectin-3 as a prognostic biomarker in heart failure. Eur J Prev Cardiol. 2015;22(9):1096-1110.
- George M, et al. Looking into the crystal ball-upcoming drugs for dyslipidemia. J Cardiovasc Pharmacol Ther. 2015;20(1):12-24.
- George M, et al. Pharmacovigilance for psychiatrists: An introduction. Indian J Psychiatry. 2014;56(2):176-181.
- George M, et al. Novel drug targets in clinical development for heart failure. Eur J Clin Pharmacol. 2014;70(7):765-774.
- George M, et al. New and emerging drug molecules against obesity. J Cardiovasc Pharmacol Ther. 2014;19(1):65-76.
- George M, et al. Clinical trials in India: Where do we stand globally? Perspect Clin Res. 2013;4(3):160-167.
- Sandhiya S, Melvin G, et al. The dawn of hedgehog inhibitors: Vismodegib. J Pharmacol Pharmacother. 2013;4(1):4-7.
- George M, et al. Newer antipsychotics and upcoming molecules for schizophrenia. Eur J Clin Pharmacol. 2013;69(8):1497-1509.